

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Company Deciphera Pharmaceuticals (ripretinib) Patient/carer groups Black Health Agency for Equality Bladder and Bowel Community Bowel Cancer Information Bowel Cancer UK Cancer Black Care Cancer52 GIST Cancer UK Guts UK Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Oesophageal Patients Association OG Support Sarcoma UK South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care 	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee Possible comparator companies None
 Healthcare professional groups Association of Cancer Physicians Association of Coloproctology of Great Britain and Ireland Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland British Geriatrics Society British Institute of Radiology British Psychosocial Oncology Society 	 Relevant research groups Bowel Research UK Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Foundation for Liver research GASTROCAN Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health and Care Research

Draft stakeholder list for the evaluation of Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496] Issue date: January 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Sarcoma Group British Society of Gastroenterology Cancer Research UK Primary Care Society for Gastroenterology Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Scottish Sarcoma Network Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Associated Public Health groups Public Health Wales UK Health Security Agency Evidence Review Group National Institute for Health Research Health Technology Assessment Programme (NETSCC) Associated Guideline Group NICE - National Guideline Alliance (cancer, mental health, and women and children's health) NICE - National Guideline Centre (Acute Care, Chronic Conditions, Nursing and Supportive Care and Primary Care)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Draft stakeholder list for the evaluation of Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496] Issue date: January 2025





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.